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Abstract: Mood disorders represent one of the most prevalent and costly psychiatric diseases
worldwide. The current therapies are generally characterized by several well-known side effects
which limit their prolonged use. The use of herbal medicine for the management of several
psychiatric conditions is becoming more established, as it is considered a safer support to conventional
pharmacotherapy. The aim of this study was to investigate the possible anxiolytic and antidepressant
activity of a fixed combination of L-theanine, Magnolia officinalis, and Melissa officinalis (TMM) in an
attempt to evaluate how the multiple modulations of different physiological systems may contribute
to reducing mood disorders. TMM showed an anxiolytic-like and antidepressant-like activity in vivo,
which was related to a neuroprotective effect in an in vitro model of excitotoxicity. The effect of TMM
was not altered by the presence of flumazenil, thus suggesting a non-benzodiazepine-like mechanism
of action. On the contrary, a significant reduction in the effect was observed in animals and neuronal
cells co-treated with AM251, a cannabinoid receptor type 1 (CB1) antagonist, suggesting that the
endocannabinoid system may be involved in the TMM mechanism of action. In conclusion, TMM
may represent a useful and safe candidate for the management of mood disorders with an innovative
mechanism of action, particularly as an adjuvant to conventional therapies.
Keywords: mood disorders; L-theanine; excitotoxicity; neuroprotection; endocannabinoid system;
CB1; flumazenil; anxiety
1. Introduction
Mood disorders are a group of psychiatric illnesses representing the most prevalent and costly
brain diseases worldwide [1]. The World Health Organization (WHO) estimates that 350 million people
are affected by depression and anxiety, and this represents a huge impact in terms of economic cost and
considering the negative impact on suffers’ quality of life [2]. The conventional management of mood
disorders is based on pharmacotherapy and psychotherapy. However, the commonly used drugs are
generally characterized by several well-known side effects which limit their prolonged use [3,4].
In recent years, the use of herbal medicine in the management of several psychiatric conditions
has become more established, as it is considered a safer support to conventional pharmacotherapy [5].
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Indeed, WHO and the European Medicines Agency describes several herbal medicinal products for
their effectiveness in the management of different mood disorders that possess different mechanisms
of action (i.e., anxyolitic: Valeriana officinalis L., Passiflora incarnata L., Lavandula angustifolia Mill.;
antidepressant: Hypericum perforatum L.; adaptogens: Rhodiola rosea L., Panax ginseng C.A. Meyer) [6,7].
Recently, research efforts have been focused on the search for other herbal species which could enlarge
the therapeutic approach.
Over the centuries, green tea (Camellia sinensis (L.) Kuntze) has been particularly used in Traditional
Chinese Medicine for its sedative effect on subjects with mood disorder [8]. Particularly, L-theanine
(TEA) is a water-soluble amino acid extracted from the leaves of C. sinensis, which has historically
been used as a relaxing agent [9]. Its sedative effect seems to be related to the modulation of a
wide range of neurotransmitters, and, in particular, to a reduction in glutamate transmission [10,11].
The glutamatergic tone is thought to act as a possible cofactor in increasing stress-related disorders
such as anxiety [12]. Nowadays, TEA is receiving considerable interest in investigating its possible
effect on cognition, mood, and brain function in humans [9].
The endocannabinoid system is an important physiological system able to influence and modulate
several processes within the central nervous system [13], including mood disorders. Indeed, in the case
of hyper-excitability, the activation of cannabinoid receptor type 1 (CB1) produces a reduction in the
glutamatergic tone in order to maintain a normal synaptic activity [14,15]. Magnolia officinalis Rehder &
E.H. Wilson plays an important role in traditional Chinese and Japanese herbal medicine, particularly
for the treatment of mood disorders [16]. Moreover, the use of Magnolia officinalis has been described
in the WHO monograph [17]. Honokiol, a neo-lignan extracted from the bark of Magnolia officinalis,
shares a structural similarity with some cannabinoid receptors ligands and has been demonstrated to
act as an agonist of CB1 [18].
Gamma aminobutyric acid (GABA) is the primary inhibitory neurotransmitter known to counteract
the hyper-excitability effect of glutamate, and for this reason the GABA system represents an important
target of anxiolytic drugs [19]. Melissa officinalis L. has been used in the treatment of anxiety and depression
also in western medicine [20]. The main constituent, rosmarinic acid, has been shown to possess a
GABA-transaminase inhibitory activity and beneficial effect on mood disorder modulation [21–23].
The aim of this study is to investigate the possible anxiolytic and anti-depressant activity of
a fixed combination of TEA, a standardized Magnolia officinalis extract enriched in honokiol, and a
standardized Melissa officinalis extract enriched in rosmarinic acid in order to evaluate how the multiple
modulations of different physiological systems may contribute to reducing mood disorders.
2. Materials and Methods
2.1. Animals
Experiments were performed on male CD1 mice (weight: 22–24 g; age: 5–7 weeks, Envigo, Varese,
Italy). The mice were randomly housed in standard cages and kept in a room at 23 ± 1 ◦C with a
12-h light/dark cycle with the light on at 7 a.m. Food (standard laboratory diet) and tap water were
available ad libitum. The cages were placed in the experimental room 24 h before behavioral testing for
acclimatization. All the tests were conducted during the light phase. The experimental protocol was
approved by the Institution’s Animal Care and Research Ethics Committee (University of Florence, Italy)
under license from the Italian Department of Health (54/2014-B). The mice were treated in accordance with
the relevant European Union (Directive 2010/63/EU, the council of 22 September 2010 on the protection
of animals used for scientific purposes) and international regulations (Guide for the Care and Use of
Laboratory Animals, US National Research Council, 2011). All the studies involving animals are reported
in accordance with the ARRIVE guidelines for experiments involving animals [24]. The experimental
protocol was designed to minimize the number of animals used and their suffering.
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The number of animals per experiment was based on a power analysis [25]. For behavioral assays,
8 animals per group were used to have a probability of 86%, at which the study detects a difference
between groups (0.05 significance level). G power software was used to calculate the sample size.
2.2. Chemical and Drug Administration
Mice were randomly assigned to each treatment group by a researcher other than the operator.
The fixed combination (TMM) of TEA (Giellepi Spa, Milan, Italy), Melissa officinalis leaf extract (MLE,
extraction solvent: ethanol 50% v/v, standardized to contain 2% rosmarinic acid, MB Med, Rivalta di
Torino, Italy), and Magnolia officinalis bark extract (MOE, extraction solvent: ethanol 96% v/v, standardized
to contain 40% honokiol, Naturex Inc., South Hackensack, NJ, USA) was formulated to contain 25% TEA,
6.25% MLE, and 2.5% MOE. An amount of 1% sodium carboxymethyl cellulose (CMC, Sigma-Aldrich,
Milan, Italy) was used as an inert excipient to solubilize the ingredients. This combination ratio was
chosen on the basis of similar food supplements marketed in Italy. The TMM was administered p.o.
60 min before the test at the dose of 10 mg/kg for all experiments except for the dose–response curve,
where doses of TMM ranging from 1 to 30 mg kg−1 p.o. were used. The control group received an
equivalent volume of the vehicle. For comparison with the single components of the combination, the
TEA, MLE, and MOE were administered at the concentration present in the active dose of TMM.
TMM, TEA, MLE, and MOE were dissolved in saline (0.9% NaCl) on the day of the experiment
and administered at a volume of 10 mL/kg by gavage (p.o.). Each treatment was administered p.o.
60 min before the behavior test.
AM251 (4 mg/kg i.p.), flumazenil (FLU, 2 mg/kg i.p.) (Tocris, Bristol, UK), diazepam (DIAZ,
1 mg/kg i.p.), and amitriptyline (AMI, 10 mg/kg i.p) (Sigma Aldrich, Milan, Italy) were administered
30 min before the tests. The above-mentioned reference drugs were dissolved in a saline solution,
except for AM251, which was dissolved in dimethyl sulfoxide/Tween 80/0.9% saline (1:1:18).
2.3. Locomotor Activity
2.3.1. Rotarod Test
The possible onset of side effects on motor performance by each treatment was assessed by a
rotarod test, as previously described [26]. The rotarod apparatus consisted of a 3 cm-diameter rod with a
non-slippery surface at a rotation rate of 16 RPM. The rod (30 cm in length) was placed at a height of 15 cm
from the base and divided into five equal sections by six disks. The animal was placed back on the rod
immediately after falling, and the integrity of the motor coordination was assessed as the number of falls
from the rod in 30 s. The test was performed 0, 15, 30, 45, 60, 90, 120, and 180 min after administration.
2.3.2. Hole-Board Test
The spontaneous locomotor activity was evaluated using the hole-board test [26]. The apparatus
consisted of an elevated arena (40 cm × 40 cm; 1 m above the floor) with 16 evenly spaced holes (3 cm
in diameter; four lines of four holes each). The mice were placed individually on the center of the board
and allowed to explore the plane freely for a period of 5 min each. The movements of the animal on
the plane (spontaneous mobility) were automatically recorded by two photo beams, crossing the plane
from the midpoint to the midpoint of opposite sides. Miniature photoelectric cells, placed in each of
the 16 holes, recorded the head-dips in the holes by the mice. This head-dipping behavior represents
the exploratory activity of the mice. The test was performed 60 min after oral administration.
2.3.3. Hot Plate Test
The hot plate test was performed as previously described [26]. The mice were placed on a hot
plate (Ugo Basile Biological Research Apparatus, Varese, Italy), with the temperature adjusted to
52.5 ± 0.1 ◦C. The reaction latencies (s) were measured with a stopwatch before (baseline latency) and
after treatments. The time to the first sign of nociception (paw licking) was recorded and the mouse
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was immediately removed from the hot plate. An arbitrary cutoff period of 45 s was adopted to avoid
damage to the paws. The test was performed 0, 15, 30, 45, 60, 90, 120 and 180 min after administration.
2.4. Anxiolytic-Like Activity
2.4.1. Light-Dark Box
The light-dark box (LDB) apparatus (length 50 cm, width 20.5 cm, and height 19 cm) consisted of
two equal acrylic compartments, one dark (black) and one illuminated by a 60 W bulb lamp (white).
A dark insert (with black walls and lid, non-transparent for visible light) was used to divide the arena
into two equal parts. The two compartments communicated by a small door (10 cm × 3.2 cm) at the
floor level in the wall of the insert that allowed the animals to move freely from one compartment to
another. Each mouse was released in the center of the light compartment with its head facing away
from the door and allowed to explore the arena for 5 min. The behavioral parameters recorded were
the time spent in the light chamber and the number of full-body transitions between chambers, since
these have been previously described as a reflection of anxiety in this apparatus [27]. After testing, the
animals were removed from the LDB and returned to their home cage in the colony room. After each
test, the apparatus was cleaned with 70% ethanol to remove the olfactory cues and to allow it to dry
before the next subject was tested. This test exploited the conflict between the animal’s tendency to
explore a new environment and its fear of bright light.
2.4.2. Marbles Test
The marble-burying behavioral test was performed as previously described [28]. All the
experiments were conducted between 10:00 and 17:00. The mice were placed individually in clear
plastic boxes (27 × 16 × 14 cm) containing 20 glass marbles (1 cm diameter) evenly spaced on sawdust
3 cm deep, without food and water. Each mouse was habituated to the behavior room for 30 min
before being placed into the cage. The results of the test were expressed as the number of marbles
buried for at least two-thirds within 30 min. The number of buried marbles is considered a measure of
animal anxiety. The observer did not know which agent was being tested.
2.4.3. Novelty Suppressed Feeding Test
The novelty suppressed feeding test (NSFT) test was performed as previously described [29]. The test
was conducted in an uncovered plastic box (40 cm × 40 cm × 30 cm). The day before the test, the animals
were acclimated for 10 min to the box and deprived of food overnight (12 h). On the day of the test,
the mice was individually placed in a corner of the box, which contained a single pellet of food in the center.
The latency to feed was recorded in 5 min. The observer did not know which agent was being tested.
2.5. Antidepressant-Like Activity
Tail Suspension Test
The tail suspension test (TST) was performed according to [30]. The mice were suspended from a
plastic rod mounted 50 cm above the floor by adhesive tape placed to the upper middle of the tail.
The time during which the mice remained immobile was measured with a stopwatch during a test
period of 6 min. The mice were considered immobile when they hung passively and completely
motionless, except for movements caused by respiration. Immobility was considered a depression-like
behavior (behavioral despair) and was measured in the first 2 min of the test, when the animals react
to the unavoidable stress, and in the last 4 min, when the behavioral despair is established.
2.6. Cell Culture
A human neuroblastoma cell line (SH-SY5Y, RRID:CVCL_0019), kindly donated by Prof. Lorenzo
Corsi (University of Modena and Reggio Emilia, Italy), was cultured in DMEM (Sigma-Aldrich) and F12
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Ham’s nutrients mixture (Sigma-Aldrich), containing 10% heat-inactivated FBS (Sigma-Aldrich), 1%
L-glutamine (Sigma-Aldrich), and 1% penicillin-streptomycin solution (Sigma-Aldrich) until confluence
(70–80%). The cells were grown in a humidified atmosphere with 5% CO2 at 37 ◦C. EDTA-trypsin
solution (Sigma-Aldrich) was used for detaching the cells from flasks, and cell counting was performed
using a hemocytometer by Trypan blue staining.
2.7. Cell Treatments
L-glutamate (GLU) was used to induce the excitotoxic stimulation of SH-SY5Y cells [31]. An 800 mM
stock solution of monosodium glutamate (Sigma Aldrich, Milan) was prepared in sterile DMEM. Later,
it was filtered and diluted in a complete medium for the cell treatments.
TMM (1 mg/mL), TEA (0.25 mg/mL), MOE (0.0625 mg/mL), and MLE (0.025 mg/mL) were dissolved in
DMEM. The stock solution was then diluted in complete DMEM to reach the final working concentration,
according to previously performed cell viability experiments (see supporting information).
The SH-SY5Y cells were pre-treated for 4 h with TMM, TEA, MOE, and MLE and then stimulated
with glutamate 80 mM for 24 h. AM251 (Tocris) at an amount of 5 µM was administered 30 min before
the pre-treatment with TMM, TEA, MOE, and MLE.
2.8. Cell Viability
Cell viability was performed using a Cell Counting Kit (CCK-8, Sigma-Aldrich) according to
the manufacturer’s instructions. A total of 5 × 105 cells/well were seeded into 96 multi-well plates
and grown to confluence. The absorbance was measured at 450 nm using a MP96 microplate reader
spectrophotometer (Safas, Monte Carlo, Principality of Monaco). The treatments were performed in
six replicates in three independent experiments, and the cell viability was calculated by normalizing
the values to the control’s mean.
2.9. Non-Competitive Sandwich ELISA Protocol for BDNF
A human brain-derived neurotrophic factor (BDNF) ELISA kit (Abcam, Milan, Italy) was used for
the dosage of BDNF in human cell culture supernatant, according to the manufacturer’s instructions.
SH-SY5Y cells (1.5 × 105) were seeded in 200 µL of complete medium in 48-well culture plates and
allowed to grow until confluence. The cells were pretreated with TMM, TEA, MLE, and MOE for 4 h
and then stimulated with glutamate 80 mM for 24 h. The supernatants were collected and stored at
−80 ◦C until analysis. The samples were analyzed in duplicate for a total of 3 independent experiments.
2.10. Data and Statistical Analysis
The data and statistical analysis in this study comply with the recommendations on experimental
design and analysis in pharmacology [32]. The behavioral data are presented as means ± SEM. Eight
mice per group were used. A two-way ANOVA followed by a Bonferroni post hoc was used for the
statistical analysis. For the locomotor activity, the unpaired sample t-test was performed. For an
in vitro analysis, the data were analyzed by a one-way ANOVA followed by a Tukey post hoc test.
For each test, a value of p < 0.05 was considered significant. GraphPad Prism version 5.0 (GraphPad
Software Inc., San Diego, CA, USA) was used for all the statistical analyses.
3. Results
3.1. Anxiolytic Effect of TMM
The LDB test aims to detect anxiety behavior in rodents, reflected by the avoidance of light areas
and a decrease in explorative activity [33].
As reported in Figure 1A, TMM increased the time spent in the light chamber. The tice treated
with TMM took less time to leave the dark compartment and spent significantly more time in the
light chamber, thus showing an anxiolytic-like effect. The effect appeared 60 min after administration
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already with the dose of 1 mg/kg and the maximum effect was obtained with 10 mg/kg. Interestingly,
at the dose of 30 mg/kg the effect disappeared, showing a biphasic bell-shaped effect.
TMM (10 mg/kg) resulted to be more effective than its constituents alone, used at the concentration
present in the active dose of TMM (Figure 1B). Indeed, TEA (2.5 mg/kg) was the only component
of TMM able to induce a significant increase in time spent in the light chamber compared to the
control group, even if with a lower intensity than TMM. No significant effects were observed after the
administration of MLE (0.625 mg/kg) and MOE (0.25 mg/kg).
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Figure 1. Dose–response curve obtained ith the oral administration of different concentrations of
TMM after 6 i i t li t/ r (L B) test (A). Comparison of th effect of T M (10 mg/kg),
L-theanine ( ) (2.5 mg/kg), Melissa officinalis leaf extract (MLE) (0.625 mg/kg), and Magnolia officinalis
bark extract (MOE) (0.25 mg/kg) in the L D test (B). Diazepam (DIAZ) was used as a positive control.
*** p< 0.001, ** p< 0.01, * p < 0.05 vs. CTRL; ◦◦◦ p < 0.001 vs. TMM.
The anxiolytic eff ctiven ss of TMM in terms of time spent in th light chamber was co parable
to that obtained with DIAZ, which was used as a reference drug.
In t e l t t, t e nu ber of marbles buried is an indicator of the em tional state of
the mice. The higher is the number of buried marbles, the higher the anxiety-like behavior [28].
The control mice buried almost all of the marbles present in the ( . ; Figure 2A,B), ile the
T (Figure 2A,C)-tr t i i i ifi tl f ( . ). e i ti f the single
co ponents sho e that TE produced an anxiolytic-like behavior co para l to T (43.75 )
(Figure 2A,D), whereas no significant effects w re observed for MLE (68.00%; Figure 2A,E) and
MOE (70.00%; Figure 2A,F). In this test, the effect in uced by DIAZ was higher than TMM; in eed,
th p rcentage of marbles buried was 12.85% (Figure 2A,G). In the NSFT, a re l t t interact
with the food pellet is considered an anxiolytic effect [34]. As reported in the Figure 2H, TMM reduced
the latency to interact with food in comparison to the control group (−35.64%). TEA also showed a
significant reduction in the latency (−27.20%), similarly to MLE, which was able to reduce significantly
the latency by approximately 48.10% compared to the control group. All of the substances described
above possess an effect comparable to DIAZ, which reduces the latency of about 45.00% compared to
the control group. Otherwise, no significant effects were observed with MOE (−8.81%).
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the marbles test (A), with representative images (B–G) and novelty suppressed feeding test (NSFT) (H).
DIAZ was used as a positive control. *** p < 0.001, ** p < 0.01 vs. CTRL; §§§ p < 0.001 vs. TMM.
3.2. Antidepressant-Like Activity in a Depressant-Like Paradigm
The effect of TMM in a depressant-like behavior task was investigated using the TST. The immobility
time sp nt by he animals which was provoked by the unavoidable stress of b ing uspended by their
tail is considered a depressive-like behavior [33]. The behavioral despair is established in the last 4 min
of th test, in which the animal possesses an antidepressant-like phenotype.
No significant effects were obs rved in the first 2 mi of the experiments (Figure 3A). TMM
induced a significant reduction in the immobility time compared to the untreated mice at 1 (−56.47%),
3 (−68.46%), and 10 (72.53%) mg/kg, with 10 mg/kg being the mos eff ctive dose (Figure 3B). Similarly
to the LDB results, no significant effec s were observed at higher doses. The antidepressant-l k effect
of TMM was comparable to that obtained with AMI (−42.54%), us d as a positiv con rol. Int restingly,
whereas the immobility time of mice treated with TMM resulted in being significantly lower than t at
of control group, no significant effect was observed in mice trea ed with TEA, LE, and MOE (+1.16%,
−7.90%, −2.50%; Figure 3C).
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and in the last 4 min (B). Effect of TMM (10 mg/kg), TEA (2.5 mg/kg), MLE (0.625 mg/kg), and MOE
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3.3. Lack of Impairment of Locomotor Behaviour and Hypersensibilization to Thermal Stimulus
The mice treated with TMM 10 mg/kg did not show any alteration in their gross behavior.
The rotarod test and the hole-board test were used to evaluate the spontaneous mobility and exploratory
activity of treated mice.
The rotarod test analysis indicated that animals treated with TMM 10 did not show impaired motor
coordination. Indeed, TMM (10 mg/kg)-treated mice showed a similar trend compared to the control
group (Figure 4A,B). In addition, the spontaneous mobility and exploratory activity were unaltered
by TMM administration compared to the control mice (Figure 4C). The alteration in glutamatergic
transmission is involved in central sensitization, which is associated with chronic pain [35]. TMM did
not alter the sensitivity to thermal stimuli compared to the control group (Figure 4D).
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and 60 min after p.o. (B). Spontaneous mobility and exploratory activity measured by the hole board
test 60 min after p.o. (C). Evaluation of the hypersensitivity by hot plate test from 0 to 180 min after
p.o. (D).
3.4. Neuroprotective Effect of TMM on SH-SY5Y euronal Cells
In order to evaluate the neuroprotective activity of TMM and its components, an in vitro excitotoxicity
model was set up by stimulating SH-SY5Y neuronal cells with increasing concentrations of GLU for 24 h.
GLU stimulation significantly reduces cell viability in a dose-dependent manner, with the concentration
of 80 mM reducing cell viability by 25%, compared to the untreated control (Figure S1A). Moreover, this
effect seems to be related to a reduction in the cell metabolic activity rather than a cytotoxic effect, as
the extracellular release of lactate dehydrogenase (LDH) was not altered by GLU 80 mM (Figure S1B).
The neuroprotective effect of TMM (1 µg/mL), TEA (0.25 µg/mL), MLE (0.0625 µg/mL), and MOE
(0.025 µg/mL) was tested by pre-treating the cells for 4 h before the GLU 80 mM stimulation.
TMM was able to counteract the excitotoxic effect by preventing the reduction in cell viability
induced by GLU. Even if with a lower potency, a similar trend was observed for TEA, MLE, and MOE
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(Figure 5A). Thus, the effect of TMM seems to be related to the sum of each components, rather than to
only one of them.
Recently, a correlation between the dysregulation of brain-derived neurotrophic factor (BDNF)
in the CNS and mood disorders has been reported [36]. In our model, the excitotoxic effect induced
by GLU produced a marked increase in BDNF release by neuronal cells, which was significantly
reduced by the pretreatment with TMM. On the contrary, the use of TEA, MLE, and MOE alone had no
significant effect on the BDNF release (Figure 5B).
Nutrients 2020, 12, x FOR PEER REVIEW 10 of 16 
 
 
Figure 5. Neuroprotective effect induced by TMM in L-glutamate (GLU)-stimulated SH-SY5Y cells 
compared to TEA, MLE, and MOE (A). Modulation of brain-derived neurotrophic factor (BDNF) 
release after GLU stimulation by TMM, TEA, MLE, and MOE (B). *** p < 0.001, ** p < 0.01 vs. CTRL; 
°°° p < 0.001, ° p < 0.05 vs. GLU. 
3.5. Involvement of Endocannabinoid System in the Final Effect of TMM 
In order to better investigate the implication of the endocannabinoid system in the anxiolytic 
effect of TMM, a pretreatment with the CB1 antagonist AM251 was administered before the L/D 
box, leading to a reduction in the effectiveness of TMM 10 mg/kg. 
In order to deepen the mechanism of action of TMM, a pretreatment with FLU (2 mg/kg), a 
GABA A benzodiazepine-binding site antagonist, was administered. The co-administration of TMM 
with FLU did not impair the TMM effectiveness, thus excluding a benzodiazepine-like mechanism 
of action (Figure 6a). The involvement of the endocannabinoid system has been confirmed also in 
vitro. Indeed, the pretreatment with AM251 reduced the neuroprotective effect of TMM (Figure 6b). 
The administration of the CB1 antagonist did not altered the effect of TEA and MLE; however, it 
induced a reduction in the neuroprotective activity of MOE. 
 
Figure 6. Comparison of the anxiolytic effect of TMM in the presence and absence of AM251 and 
Figure 0. Vs. CTRL; § p < 0.05 vs. TMM (A). Comparison of the effect on the SH-SY5Y cell viability in 
the presence and absence of AM251. *** p < 0.001 vs. CTRL; °°° p < 0.001 vs. GLU; °° p < 0.01 vs. GLU 
; ° p < 0.05 vs. GLU; §§ p < 0.01vs. vehicle; § p < 0.05 vs. vehicle (B). 
4. Discussion 
Mood disorders are the most common and prevalent behavioral disorders and can result in 
significant impairment of patients’ quality of life [37]. Anxiety disorders are among the most 
prevalent psychiatric disorders worldwide, with their pharmacological treatments often being 
unsatisfying. The development of alternative therapies for the management of these pathological 
conditions, hence, is of much interest. In recent years, the role of herbal medicine in the treatment of 
mood disorders has become more established [5]. From this perspective, we have focused this study 
on the effect of a fixed combination of TEA, MOE, and MLE in order to evaluate how the multiple 
Figure 5. Neuroprotective effect induced by TMM in L-glutamate (GLU)-stimulated SH-SY5Y cells
compared to TEA, MLE, and MOE (A). Modulation of brain-derived neurotrophic factor (BDNF)
release after GLU stimulation by TMM, TEA, MLE, and MOE (B). *** p < 0.001, ** p < 0.01 vs. CTRL;
◦◦◦ p < 0.001, ◦ p < 0.05 vs. GLU.
3.5. Involvement of Endocannabinoid System in the Final Effect of T
In order to better investigate the implication of the endocannabinoid system in the anxiolytic
effect of TMM, a pretreatment with the CB1 antagonist AM251 was administered before the L/D box,
leading to a reduction in the effectiveness of TMM 10 mg/kg.
In order to deepen the mechanism of action of TMM, a pretreatment with FLU (2 mg/kg),
a GABA A benzodiazepine-binding site antagonist, was administered. The co-administration of TMM
with FLU did not impair the TMM effectiveness, thus excluding a benzodiazepine-like mechanism
of action (Figure 6A). The involvement of the endocannabinoid system has been confirmed also
in vitro. Indeed, the pretreatment with AM251 reduced the neuroprotective effect of TMM (Figure 6B).
The administration of the CB1 antagonist did not altered the effect of TEA and MLE; however, it induced
a reduction in the neuroprotective activity of MOE.
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4. Discussion
Mood disorders are the most common and prevalent behavioral disorders and can result in
significant impairment of patients’ quality of life [37]. Anxiety disorders are among the most prevalent
psychiatric disorders worldwide, with their pharmacological treatments often being unsatisfying.
The development of alternative therapies for the management of these pathological conditions, hence,
is of much interest. In recent years, the role of herbal medicine in the treatment of mood disorders has
become more established [5]. From this perspective, we have focused this study on the effect of a fixed
combination of TEA, MOE, and MLE in order to evaluate how the multiple modulation of different
physiological systems, such as the glutamatergic, GABA-ergic, and cannabinoid, may cooperate in
reducing the symptoms associated with mood disorders. In our experiments, we demonstrated that a
single oral administration of TMM was able to reduce anxiety behavior compared to the control group
after 60 min, with an efficacy comparable to that of diazepam, which was used as a benzodiazepine
positive control. The TMM efficacy was higher than its components alone, highlighting a synergistic
mechanism of action. We also found that the dose-effect relationship of TMM was biphasic, showing a
bell-shaped effect. Natural products have been frequently shown to have a biphasic pharmacological
effect, both in vitro and in vivo [38–40]. In particular, we previously reported that a standardized
Hypericum perforatum L. extract, which is a well-known anti-depressant herbal drug, can exert an
anti-nociceptive effect in mice models of neuropathic pain at lower doses compared to the one used
for treating depression, with a mechanism of action involving the opioid system. This effect was not
observed when administering higher doses, thus confirming the biphasic trend [41].
Anxiety and depression are often comorbid conditions [42]. WHO declared that 320 million
people suffer from depression, and the number is increased if “low mood” subjects are included.
Antidepressant and anxiolytics drugs often result in being ineffective [43,44] and/or cause intolerable
side effects [45]. Thus, a drug candidate claimed to be safe and effective for both anxiety and
depression would represent the ideal therapy. TMM showed an interesting antidepressant-like
activity in TST compared to amitriptyline (a conventional tricyclic antidepressant drug), while no
significant effects were observed administering its components alone. TEA has been reported to possess
antidepressant effects in humans and animal studies. Indeed, Hidese and co-workers showed that
8 weeks administration of TEA (250 mg/day) had beneficial effects on depressive symptoms, anxiety,
sleep disorders, and cognitive impairment in patients with mild major depressive disorders [46].
The antidepressant-like activity of repeated TEA (0.4–20 mg/kg) administration was also confirmed
in vivo using the open-field test, the forced swim test, the elevated plus-maze test, the prepulse
inhibition of acoustic startle, the tail suspension test„ and the reserpine test [47,48]. On the contrary,
in our study we were not able to observe an antidepressant-like effect for TEA alone. This negative
result could be due to differences in the doses, administration route, and schedule compared to the
other studies. Our results suggest an additive effect between TEA, MLE and MOE and showed the
peculiar dual activity of TMM as an antidepressant and anxiolytic agent. Moreover, differently from
other conventional drugs [49], TMM did not induce sedation or alteration in motor coordination, thus
representing a clinical advantage for long-term therapies.
Recently, it was found that 4 weeks of administration of TEA (200 mg/day) was also able to
reduce stress-related symptoms and improve cognitive functions in healthy adults [50]. Moreover,
TEA was reported to possess beneficial effects in the treatment of anxiety and sleep disturbance [51–53].
Its activity seems to involve the inhibition of presynaptic glutamate release [11] and antagonism at the
N-metyl-D-aspartate (NMDA) and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)
glutamate receptors [54], leading to a reduction in over-activated glutamatergic neurotransmission.
Interestingly, TEA (250 mg/day for 8 weeks) was reported to ameliorate positive symptoms and sleep
quality in patients with schizophrenia by stabilizing the glutamatergic concentration in the brain [55].
The modulation of glutamate levels in brain by TEA was further confirmed in vivo by Ogawa and
collaborators, who reported that L-theanine enhances anxiolytic effects, reducing the cerebrospinal
fluid glutamate concentration [56].
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The glutamatergic system has been demonstrated to possess a key role in the pathogenesis of
anxiety [12]. Indeed, the administration of NMDA and non-NMDA glutamate receptors antagonists
into the basolateral amygdala was reported to reduce anxiety in animal models [57]. Moreover,
the balance between GABA receptor-mediated inhibition and glutamate receptor-mediated excitation
regulates the behavioral and physiological responses associated with anxiety [58]. Melissa officinalis
has been shown to possess anxiolytic and anti-depressant activity by modulating GABA transmission
in animal models [23,59,60] and humans [61]. Particularly, Awad and co-workers demonstrated that
rosmarinic acid was the main responsible for the anxiolytic effect of Melissa officinalis [23].
Interestingly, the cross-talk between GABA-ergic and glutamatergic neurotransmission has been
reported to be mediated by the CB1 receptor [62]. Honokiol, a lignan extracted from Magnolia officinalis,
has been shown to act as a potent full agonist at the CB1 receptor [18], and studies conducted with
Magnolia officinalis bark extracts have reported possible anxiolytic activity without significant side
effects [63,64].
In order to deeply investigate the synergism between TMM components, we evaluated the
neuroprotective effect of TMM and its single components in an in vitro model of excitotoxicity. GLU is
the major excitatory neurotransmitter in the brain and it modulates a plethora of functions, such as
memory, pain motor function, and mood tone [65]. Indeed, the glutamate system has been successfully
targeted in both pre-clinical and clinical studies, providing a good efficacy in the treatment of anxiety
disorders [66]. In vitro models of GLU-induced neuronal damage have been widely used to test the
mechanism of action of well-known anxiolytic drugs or novel neuroprotective candidates [67–69].
By inducing excitotoxicity in SH-SY5Y neuronal cells with GLU, we demonstrated the neuroprotective
effect of TMM. A weaker effect was obtained with its components alone. BDNF is a neurotrophin
which is pivotal for the survival, growth, and maintenance of neurons in key brain circuits involved
in emotional and cognitive function. Indeed, the alteration of the normal BDNF level is strongly
linked with mood disorder manifestation [70–72]. The glutamate receptor-mediated BDNF release a
main evidence of a cooperative interaction between BDNF and GLU [73,74]. Indeed, the excitotoxic
cascade in neurons stimulates the release of BDNF as a defense mechanism against the oxidative stress
produced by the hyper-activation of the glutamate receptor [75,76]. The pre-treatment with TMM
completely prevented the GLU-increased release of BDNF in SH-SY5Y, highlighting a protective effect
against excitotoxicity. On the contrary, TEA, MLE, and MOE alone were not able to counteract this
effect. Benzodiazepines are characterized by a reduced patient compliance because of their well-known
side effects [77]. In order to exclude a benzodiazepine-like mechanism of action of TMM, we treated
mice in the presence of FLU, a well-known benzodiazepine antagonist [78]. The effect of TMM was
not altered by the presence of FLU, thus suggesting a non-benzodiazepine-like mechanism of action.
On the contrary, a significant reduction in the effect was observed in animals and neuronal cells
co-treated with AM251, a CB1 antagonist [79], and TMM. Confirming the reliability of our model,
the MOE effect was significantly reduced by the CB1 antagonist. This is consistent with the reported
CB1 agonist activity of MOE constituents in neuronal cells [18].
5. Conclusions
The results obtained in this study highlighted that the co-administration of a GABA-modulating
agent (MLE), a modulator of the glutamate receptor (TEA), and a modulator of the CB1 receptor
(MOE) could be suggested as a novel and interesting anxiolytic and antidepressant strategy, with a
neuroprotective effect against excitotoxicity and being devoid of the typical side effects of anxiolytic
drugs. TMM may represent a useful and safe approach for the management of mood disorders in
pre-clinical forms or in case of low mood, as well as an adjuvant to conventional therapies.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/12/6/1803/
s1, Figure S1: Effect of increasing concentration of GLU on SH-SY5Y cell viability, evaluated by CCK-8 kit
(Sigma-Aldrich, Milan, Italy) (A). The cytotoxic potential of the stimulus was excluded by measuring the lactate
dehydrogenase (LDH) release, using LDH activity assay (Sigma-Aldrich, Milan, Italy).
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